PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy

[1]  Yemi Kim,et al.  Predicting neo‐adjuvant chemotherapy response and progression‐free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F‐18 FDG PET/CT and diffusion‐weighted MR imaging , 2019, The breast journal.

[2]  V. Goh,et al.  Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET? , 2018, Molecular Imaging and Biology.

[3]  YingJian Zhang,et al.  Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. , 2018, The oncologist.

[4]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  B. Kaufman,et al.  Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. , 2018, Breast.

[6]  A. Alavi,et al.  Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application. , 2018, PET clinics.

[7]  V. Pérez-García,et al.  Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate , 2018, Annals of Nuclear Medicine.

[8]  S. Dhesy-Thind,et al.  Clinical practice guidelines in breast cancer. , 2018, Current oncology.

[9]  Vivek Verma,et al.  Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy , 2018, Breast Cancer Research and Treatment.

[10]  D. Groheux,et al.  Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Walter Noordzij,et al.  Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer. , 2018, Radiology.

[12]  N. Houssami,et al.  Rapid review: radiomics and breast cancer , 2018, Breast Cancer Research and Treatment.

[13]  D. Molina,et al.  Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline 18F-FDG PET/CT in breast cancer with neoadjuvant chemotherapy indication. , 2017, Revista espanola de medicina nuclear e imagen molecular.

[14]  Isabella Castiglioni,et al.  [18F]FDG PET/CT features for the molecular characterization of primary breast tumors , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  H. Tesch,et al.  Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project , 2017, Breast Cancer Research and Treatment.

[16]  S. Bae,et al.  Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013 , 2017, Nuclear Medicine and Molecular Imaging.

[17]  D. Groheux,et al.  Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Steffen Löck,et al.  Image biomarker standardisation initiative - feature definitions , 2016, ArXiv.

[19]  A. G. García Vicente,et al.  Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach. , 2016, Revista espanola de medicina nuclear e imagen molecular.

[20]  Yemi Kim,et al.  Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ , 2015, European Radiology.

[21]  K. Kitajima,et al.  Association between 18F-FDG uptake and molecular subtype of breast cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  M. Dank,et al.  Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer , 2015, Nuclear medicine communications.

[23]  Wayne Rochester,et al.  IMOS National Reference Stations: A Continental-Wide Physical, Chemical and Biological Coastal Observing System , 2014, PloS one.

[24]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  S. Son,et al.  Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast , 2014, BMC Cancer.

[26]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[27]  M. Soussan,et al.  Relationship between Tumor Heterogeneity Measured on FDG-PET/CT and Pathological Prognostic Factors in Invasive Breast Cancer , 2014, PloS one.

[28]  Won Hwa Kim,et al.  18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes , 2014, European Radiology.

[29]  S. Kurata,et al.  The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancer , 2013, Nuclear medicine communications.

[30]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Tapio Salakoski,et al.  A comparison of AUC estimators in small-sample studies , 2009, MLSB.

[32]  Patrick Royston,et al.  How should variable selection be performed with multiply imputed data? , 2008, Statistics in medicine.

[33]  Luigi Salmaso,et al.  Model performance analysis and model validation in logistic regression , 2007 .

[34]  E Provenzano,et al.  Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy , 2007, Histopathology.

[35]  T. Stijnen,et al.  Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.

[36]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[37]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[38]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[39]  A. G. García Vicente,et al.  Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT , 2013, European journal of nuclear medicine and molecular imaging.